182 related articles for article (PubMed ID: 27735863)
21. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
22. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid.
Myers MB; McKim KL; Parsons BL
Mol Carcinog; 2014 Feb; 53(2):159-67. PubMed ID: 22930660
[TBL] [Abstract][Full Text] [Related]
23. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
[TBL] [Abstract][Full Text] [Related]
24. Association of the miR-149 Rs2292832 polymorphism with papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population.
Wei WJ; Lu ZW; Li DS; Wang Y; Zhu YX; Wang ZY; Wu Y; Wang YL; Ji QH
Int J Mol Sci; 2014 Nov; 15(11):20968-81. PubMed ID: 25405731
[TBL] [Abstract][Full Text] [Related]
25. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
26. Cribriform-morular variant of papillary thyroid carcinoma: a study of 3 cases featuring the PIK3CA mutation.
Kwon MJ; Rho YS; Jeong JC; Shin HS; Lee JS; Cho SJ; Nam ES
Hum Pathol; 2015 Aug; 46(8):1180-8. PubMed ID: 26054797
[TBL] [Abstract][Full Text] [Related]
27. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
28. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel.
Silva AL; Carmo F; Bugalho MJ
Eur J Endocrinol; 2013 Jun; 168(6):795-804. PubMed ID: 23482591
[TBL] [Abstract][Full Text] [Related]
29. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
30. High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2005 Feb; 24(8):1455-60. PubMed ID: 15608681
[TBL] [Abstract][Full Text] [Related]
31. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
32. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies.
Wei WJ; Lu ZW; Wang Y; Zhu YX; Wang YL; Ji QH
Cancer Genet; 2015 Mar; 208(3):68-75. PubMed ID: 25746573
[TBL] [Abstract][Full Text] [Related]
35. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
36. Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma.
Lin S; Meng W; Zhang W; Liu J; Wang P; Xue S; Chen G
J Int Med Res; 2013 Jun; 41(3):568-72. PubMed ID: 23685895
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
40. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
